Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study

Myo-inositol’s role in improving acne by reducing hyperandrogenism has been demonstrated in PCOS patients. Inositol and associated molecules display inhibitory properties against 5-α reductase, COX-2, and lipase enzymes in addition to their antimicrobial and anti-inflammatory properties. However, th...

Full description

Saved in:
Bibliographic Details
Main Authors: Ezhil Arasan Ramanan, Sailatha Ravi, K. R. Radha Anbu, Margaret Michael
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Dermatology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/7019126
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560649892265984
author Ezhil Arasan Ramanan
Sailatha Ravi
K. R. Radha Anbu
Margaret Michael
author_facet Ezhil Arasan Ramanan
Sailatha Ravi
K. R. Radha Anbu
Margaret Michael
author_sort Ezhil Arasan Ramanan
collection DOAJ
description Myo-inositol’s role in improving acne by reducing hyperandrogenism has been demonstrated in PCOS patients. Inositol and associated molecules display inhibitory properties against 5-α reductase, COX-2, and lipase enzymes in addition to their antimicrobial and anti-inflammatory properties. However, the role of myo-inositol is not well established in women patients with normal hormone levels but with clinical manifestations of PCOS. In this study, we evaluate the efficacy of Tracnil™, a combination of myo-inositol with folic acid and vitamin D3, in resolving acne in overweight women of menstruation age displaying normal hormone levels. It is a single-arm study conducted at 2 centers including 33 women with acne, hirsutism, and menstrual irregularities. Acne and hirsutism were assessed by manual lesion count, modified Cook’s scale, and modified Ferriman–Gallwey hirsutism score (mFGHS). Hormone levels and safety parameters were assessed throughout the study. Our results show that Tracnil™ monotherapy could drastically reduce acne-related lesions of both inflammatory and noninflammatory types as quickly as 8 weeks. Additionally, it improves hirsutism and menstrual irregularities. Adverse reactions were negligible during the whole study period with no drastic side effects reflected by a modulatory effect on hormone levels. Despite the subjects having normal hormone levels, the acne treatment with myo-inositol and vitamin D3 shows improvement in hirsutism and regularization of menstrual cycle. Therefore, we attribute the mechanism of action of Tracnil™ to modulation of receptor sensitivity to sex hormones or other downstream processing events. Tracnil™ may be considered as a first-line treatment for dermatological manifestations of PCOS even in the absence of significant hormonal abnormalities. This treatment is practically implementable in a dermatologists’s office practise.
format Article
id doaj-art-1d710abe71cd433188888d77cae8fc5d
institution Kabale University
issn 1687-6105
1687-6113
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Dermatology Research and Practice
spelling doaj-art-1d710abe71cd433188888d77cae8fc5d2025-02-03T01:26:58ZengWileyDermatology Research and Practice1687-61051687-61132020-01-01202010.1155/2020/70191267019126Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm StudyEzhil Arasan Ramanan0Sailatha Ravi1K. R. Radha Anbu2Margaret Michael3Dr. VRE Research Laboratories, Chennai 600078, IndiaMedlish Communications, Chennai 600078, IndiaAnbu Clinic, Chennai 600020, IndiaPristine Hospital and Research Centre, Bengaluru 560086, IndiaMyo-inositol’s role in improving acne by reducing hyperandrogenism has been demonstrated in PCOS patients. Inositol and associated molecules display inhibitory properties against 5-α reductase, COX-2, and lipase enzymes in addition to their antimicrobial and anti-inflammatory properties. However, the role of myo-inositol is not well established in women patients with normal hormone levels but with clinical manifestations of PCOS. In this study, we evaluate the efficacy of Tracnil™, a combination of myo-inositol with folic acid and vitamin D3, in resolving acne in overweight women of menstruation age displaying normal hormone levels. It is a single-arm study conducted at 2 centers including 33 women with acne, hirsutism, and menstrual irregularities. Acne and hirsutism were assessed by manual lesion count, modified Cook’s scale, and modified Ferriman–Gallwey hirsutism score (mFGHS). Hormone levels and safety parameters were assessed throughout the study. Our results show that Tracnil™ monotherapy could drastically reduce acne-related lesions of both inflammatory and noninflammatory types as quickly as 8 weeks. Additionally, it improves hirsutism and menstrual irregularities. Adverse reactions were negligible during the whole study period with no drastic side effects reflected by a modulatory effect on hormone levels. Despite the subjects having normal hormone levels, the acne treatment with myo-inositol and vitamin D3 shows improvement in hirsutism and regularization of menstrual cycle. Therefore, we attribute the mechanism of action of Tracnil™ to modulation of receptor sensitivity to sex hormones or other downstream processing events. Tracnil™ may be considered as a first-line treatment for dermatological manifestations of PCOS even in the absence of significant hormonal abnormalities. This treatment is practically implementable in a dermatologists’s office practise.http://dx.doi.org/10.1155/2020/7019126
spellingShingle Ezhil Arasan Ramanan
Sailatha Ravi
K. R. Radha Anbu
Margaret Michael
Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
Dermatology Research and Practice
title Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
title_full Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
title_fullStr Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
title_full_unstemmed Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
title_short Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study
title_sort efficacy and safety of tracnil™ administration in patients with dermatological manifestations of pcos an open label single arm study
url http://dx.doi.org/10.1155/2020/7019126
work_keys_str_mv AT ezhilarasanramanan efficacyandsafetyoftracniladministrationinpatientswithdermatologicalmanifestationsofpcosanopenlabelsinglearmstudy
AT sailatharavi efficacyandsafetyoftracniladministrationinpatientswithdermatologicalmanifestationsofpcosanopenlabelsinglearmstudy
AT krradhaanbu efficacyandsafetyoftracniladministrationinpatientswithdermatologicalmanifestationsofpcosanopenlabelsinglearmstudy
AT margaretmichael efficacyandsafetyoftracniladministrationinpatientswithdermatologicalmanifestationsofpcosanopenlabelsinglearmstudy